BGI Genomics and partners revealed cfDNA's 'genetic code' characteristics, advancing liquid biopsy precision for NIPT and early cancer screening.
Understanding the 'genetic code' of cfDNA is a significant step towards more accurate and reliable liquid biopsies. This could enhance the efficacy of early cancer detection and NIPT, potentially leading to earlier interventions and improved patient outcomes. It also strengthens BGI's position as a leader in genomic diagnostics and personalized medicine.
BGI and partners revealed cfDNA's 'genetic code' characteristics.
This research advances the precision of liquid biopsies.
Findings are relevant for NIPT and early cancer screening.
The research involves Chinese institutions and is published in a scientific context, indicating advancements in biotechnology and medical research within East Asia.
This research advances the precision of liquid biopsies.
Findings are relevant for NIPT and early cancer screening.
Sign in to save notes on signals.
Sign In